NOW IS THE TIME:
DETECT ANTI-JCV ANTIBODIES AND ASSESS PML RISK
Testing for anti-JC virus (JCV) antibodies is recommended in patients considering or receiving TYSABRI1
Anti-JCV antibody negative status indicates that exposure to JCV has not been detected1
IT IS RECOMMENDED THAT ANTI-JCV ANTIBODY NEGATIVE PATIENTS BE RETESTED EVERY 6 MONTHS.1
Anti-JCV antibody positive status is 1 of 3 known risk factors that increase the risk of PML1
THE RISKS AND BENEFITS OF CONTINUING TYSABRI SHOULD BE CAREFULLY CONSIDERED IN PATIENTS WHO ARE ANTI-JCV POSITIVE AND HAVE ONE OR MORE ADDITIONAL RISK FACTORS.1
- TYSABRI Prescribing Information. Cambridge, MA: Biogen Idec.
- Sunyaev SR, Lugovskoy A, Simon K, Gorelik L. Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet. 2009;5(2):e1000368. Epub 2009 Feb 6.
- Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68(3):295-303.
- Data on file, Biogen Idec.